ATE554172T1 - Proteinfragmente die polyepitope der proteine e6 und e7 von hpv umfassen, deren herstellung und verwendung insbesondere zur impfung - Google Patents

Proteinfragmente die polyepitope der proteine e6 und e7 von hpv umfassen, deren herstellung und verwendung insbesondere zur impfung

Info

Publication number
ATE554172T1
ATE554172T1 AT00938875T AT00938875T ATE554172T1 AT E554172 T1 ATE554172 T1 AT E554172T1 AT 00938875 T AT00938875 T AT 00938875T AT 00938875 T AT00938875 T AT 00938875T AT E554172 T1 ATE554172 T1 AT E554172T1
Authority
AT
Austria
Prior art keywords
derivatives
induce
ctl
retro
hiv
Prior art date
Application number
AT00938875T
Other languages
English (en)
Inventor
Jeannine Choppin
Villada Isabelle Bourgault
Jean-Gerard Guillet
Francine Connan
Estelle Ferries
Original Assignee
Assist Publ Hopitaux De Paris
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assist Publ Hopitaux De Paris, Inst Nat Sante Rech Med filed Critical Assist Publ Hopitaux De Paris
Application granted granted Critical
Publication of ATE554172T1 publication Critical patent/ATE554172T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00938875T 1999-06-03 2000-05-31 Proteinfragmente die polyepitope der proteine e6 und e7 von hpv umfassen, deren herstellung und verwendung insbesondere zur impfung ATE554172T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9907012A FR2794370B1 (fr) 1999-06-03 1999-06-03 Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
PCT/FR2000/001513 WO2000075336A2 (fr) 1999-06-03 2000-05-31 Fragment proteiques polyepitopiques des proteines e6 et e7 de hpv, leur obtention et leurs utilisations notamment en vaccination

Publications (1)

Publication Number Publication Date
ATE554172T1 true ATE554172T1 (de) 2012-05-15

Family

ID=9546327

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00936995T ATE448244T1 (de) 1999-06-03 2000-05-31 Proteinfragmente die polyepitope des nef proteins von hiv umfassen, deren herstellung und verwendungen insbesondere zur impfung
AT00938875T ATE554172T1 (de) 1999-06-03 2000-05-31 Proteinfragmente die polyepitope der proteine e6 und e7 von hpv umfassen, deren herstellung und verwendung insbesondere zur impfung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00936995T ATE448244T1 (de) 1999-06-03 2000-05-31 Proteinfragmente die polyepitope des nef proteins von hiv umfassen, deren herstellung und verwendungen insbesondere zur impfung

Country Status (9)

Country Link
US (3) US6783763B1 (de)
EP (3) EP2267132B1 (de)
AT (2) ATE448244T1 (de)
AU (2) AU5229400A (de)
CA (2) CA2375602A1 (de)
DE (1) DE60043299D1 (de)
ES (2) ES2386803T3 (de)
FR (1) FR2794370B1 (de)
WO (2) WO2000075181A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
CN1440462A (zh) * 2000-04-28 2003-09-03 麦康公司 鉴定和生产抗原肽的方法并且将其用作疫苗
EP1213299A1 (de) * 2000-12-08 2002-06-12 Leids Universitair Medisch Centrum Immunogene epitopen des menschlichen Papillom-Virus und deren Anwendung
EP2112157B1 (de) * 2000-12-08 2014-07-23 Academisch Ziekenhuis Leiden Lange Peptide aus 22-45 Aminosäureresten, die die antigenspezifischen Immunreaktionen induzieren und/oder verbessern
ES2724121T3 (es) 2000-12-08 2019-09-06 Academisch Ziekenhuis Leiden Péptidos largos de 22-45 residuos de aminoácidos que inducen y/o mejoran las respuestas inmunológicas específicas para antígenos
FR2820425B1 (fr) * 2001-02-08 2004-01-02 Commissariat Energie Atomique Melange de peptides issus d'une proteine nef et leurs applications
US6933123B2 (en) * 2001-04-05 2005-08-23 Yao Xiong Hu Peptides from the E2, E6, and E7 proteins of human papilloma viruses 16 and 18 for detecting and/or diagnosing cervical and other human papillomavirus associated cancers
FR2824326B1 (fr) * 2001-05-04 2004-03-19 Commissariat Energie Atomique Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
SG185137A1 (en) * 2001-07-13 2012-11-29 Cms Peptides Patent Holding Company Ltd Biologically active peptides
CN1213062C (zh) 2001-07-13 2005-08-03 一泰医药研究（深圳）有限公司 序列号13的生物活性肽
EP1806410A3 (de) * 2001-08-23 2007-10-24 Merck & Co., Inc. Floureszente, multiplexe HPV-PCR-Assays unter Verwendung multipler Fluorophore
MXPA04005382A (es) 2001-11-07 2005-02-24 Mannkind Corp Vectores de expresion que codifican epitopes de antigenos asociados al objetivo y metodos para su diseno.
WO2004035795A1 (en) * 2002-10-17 2004-04-29 Bioleaders Corporation Vector for anti-hpv vaccine and transformed microorganism by the vector
JP2007528838A (ja) * 2003-12-24 2007-10-18 ライデン ユニバーシティ メディカル センター 腫瘍特異的ワクチンとしての合成タンパク質
EP1732598A4 (de) * 2003-12-31 2009-08-26 Pharmexa Inc Auslösung von zellulären immunantworten gegen den humanen papillovirus unter verwendung von peptid und nucleinsäure-zusammensetzungen
US10941353B2 (en) 2004-04-28 2021-03-09 Hydrocarbon Technology & Innovation, Llc Methods and mixing systems for introducing catalyst precursor into heavy oil feedstock
US7517446B2 (en) * 2004-04-28 2009-04-14 Headwaters Heavy Oil, Llc Fixed bed hydroprocessing methods and systems and methods for upgrading an existing fixed bed system
MXPA06012528A (es) 2004-04-28 2007-08-02 Headwaters Heavy Oil Llc Metodos y sistemas de hidroprocesamiento de lecho ebullente y metodos para mejorar un sistema de lecho ebullente existente.
ATE476528T1 (de) 2004-12-08 2010-08-15 Gen Probe Inc Nukleinsäuredetektion aus verschiedenen typen des humanen papillomavirus
US20070037180A1 (en) * 2005-02-10 2007-02-15 Olle Nilsson Site-specific immunization in order to establish antibodies with specificity for the E7 oncoprotein of high-risk HPV's
US7723472B2 (en) * 2005-02-28 2010-05-25 The Regents Of The University Of California Extracellular matrix binding chimeric proteins and methods of use thereof
KR102511874B1 (ko) * 2006-07-28 2023-03-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 백신 및 이의 사용 방법
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
EP2468763B1 (de) * 2007-05-31 2014-06-18 Academisch Ziekenhuis Leiden h.o.d.n. LUMC HPV-Epitope als Ziel für zervikale Tumoren infiltrierende T-Zellen zur Verwendung bei Impfstoffen
US8652482B2 (en) * 2007-10-03 2014-02-18 The Board Of Trustees Of The University Of Arkansas HPV E6 protein T cell epitopes and uses thereof
US20110110974A1 (en) * 2007-10-29 2011-05-12 Erik Depla Methods and kits for inducing a ctl response using a prime boost regimen
JP5267969B2 (ja) * 2007-12-04 2013-08-21 学校法人慶應義塾 癌ワクチン
AU2009236306B2 (en) 2008-04-17 2015-04-02 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
US8586707B2 (en) * 2008-09-16 2013-11-19 The Research Foundation Of State University Of New York Stapled peptides and method of synthesis
KR101471043B1 (ko) * 2009-01-08 2014-12-09 주식회사 바이오리더스 안정적인 항시적 고발현 자궁경부암 치료백신용 벡터 및 그에 의해 형질전환된 재조합 유산균
US8658176B2 (en) * 2009-06-22 2014-02-25 National Health Research Institutes Lipidated tumor-associated antigens and immunotherapeutic compositions
WO2011017162A2 (en) * 2009-08-03 2011-02-10 The Johns Hopkins University Methods for enhancing antigen-specific immune responses
EP2678442B1 (de) 2011-02-24 2019-01-16 QIAGEN Gaithersburg, Inc. Materialien und verfahren für den nachweis von hpv-nukleinsäuren
WO2013039989A1 (en) 2011-09-12 2013-03-21 Pds Biotechnology Corporation Particluate vaccine formulations
US9790440B2 (en) 2011-09-23 2017-10-17 Headwaters Technology Innovation Group, Inc. Methods for increasing catalyst concentration in heavy oil and/or coal resid hydrocracker
US10286064B2 (en) 2012-06-15 2019-05-14 Pds Biotechnology Corporation Cationic lipid vaccine compositions and methods of use
US9644157B2 (en) 2012-07-30 2017-05-09 Headwaters Heavy Oil, Llc Methods and systems for upgrading heavy oil using catalytic hydrocracking and thermal coking
AU2013317805B2 (en) 2012-09-21 2018-07-26 Pds Biotechnology Corporation Improved vaccine compositions and methods of use
CN103342738B (zh) * 2013-07-24 2015-02-18 广州恒上医药技术有限公司 人乳头瘤病毒e6蛋白可诱发同源蛋白间交叉反应性抗体的精细表位肽
WO2016005789A1 (en) * 2014-07-07 2016-01-14 Institut Pasteur Broad range gene and genotype papillomavirus transcriptome as a biomarker of papillomavirus- associated cancer stages
EP3421046A1 (de) 2014-11-04 2019-01-02 Janssen Vaccines & Prevention B.V. Therapeutische hpv16-impfstoffe
HK1252967A1 (zh) 2015-08-20 2019-06-06 Janssen Vaccines & Prevention B.V. 治疗性hpv18疫苗
US11414608B2 (en) 2015-09-22 2022-08-16 Hydrocarbon Technology & Innovation, Llc Upgraded ebullated bed reactor used with opportunity feedstocks
US11414607B2 (en) 2015-09-22 2022-08-16 Hydrocarbon Technology & Innovation, Llc Upgraded ebullated bed reactor with increased production rate of converted products
US11612652B2 (en) 2015-11-13 2023-03-28 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
EP3452087A1 (de) 2016-05-02 2019-03-13 Janssen Vaccines & Prevention B.V. Therapeutische hpv-impfstoffkombinationen
JP2019517522A (ja) * 2016-06-03 2019-06-24 エトゥビクス コーポレーション ヒトパピローマウイルス（ｈｐｖ）関連疾患の処置のための組成物及び方法
US11421164B2 (en) 2016-06-08 2022-08-23 Hydrocarbon Technology & Innovation, Llc Dual catalyst system for ebullated bed upgrading to produce improved quality vacuum residue product
CN117018170A (zh) 2016-06-20 2023-11-10 Isa制药有限公司 肽疫苗制剂
CN108164587A (zh) * 2016-12-07 2018-06-15 中国医学科学院肿瘤医院 新的hpv抗原表位
JP7336831B2 (ja) 2017-03-02 2023-09-01 ハイドロカーボン テクノロジー アンド イノベーション、エルエルシー ファウリングが少ない堆積物を伴う改良された沸騰床リアクター
US11732203B2 (en) 2017-03-02 2023-08-22 Hydrocarbon Technology & Innovation, Llc Ebullated bed reactor upgraded to produce sediment that causes less equipment fouling
TW201924722A (zh) 2017-12-05 2019-07-01 美商Ｐｄｓ生技公司 用於刺激第i型干擾素基因之方法及包含陽離子脂質的組合物
CN111868074A (zh) * 2018-01-24 2020-10-30 昆士兰医学研究所理事会 Hpv免疫疗法
CA3057131C (en) 2018-10-17 2024-04-23 Hydrocarbon Technology And Innovation, Llc Upgraded ebullated bed reactor with no recycle buildup of asphaltenes in vacuum bottoms
US12497569B2 (en) 2022-05-26 2025-12-16 Hydrocarbon Technology & Innovation, Llc Method and system for mixing catalyst precursor into heavy oil using a high boiling hydrocarbon diluent
EP4701650A2 (de) 2023-04-26 2026-03-04 Isabella Pharma B.V. Verfahren zur behandlung von krebs durch verabreichung immunogener zusammensetzungen und eines pd-1-inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
FR2641081A1 (de) * 1988-12-23 1990-06-29 Medgenix Group
CA2038581A1 (en) 1990-03-20 1991-09-21 Martin Muller Seroreactive epitopes of human papillomavirus (hpv) 16 proteins
US5932412A (en) * 1990-05-11 1999-08-03 Euro-Diagnostica Ab Synthetic peptides in human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunoassay for diagnostic purposes
ES2193133T3 (es) 1991-07-13 2003-11-01 Dade Behring Marburg Gmbh Uso de peptidos derivados de los genes e6 y e7 de hpv-16 para fines.
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
IL105554A (en) 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
EP0728764A4 (de) * 1993-10-19 1999-01-20 Ajinomoto Kk Peptide das eine immunantwort gegen hiv unduziert und arzneimittel die esenthaelt zur vorbeugung oder behandlung von aids
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
DE69723434T2 (de) * 1996-04-26 2004-05-19 Rijksuniversiteit Te Leiden Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
FR2771640B1 (fr) * 1997-12-03 2000-02-11 Inst Nat Sante Rech Med Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques

Also Published As

Publication number Publication date
AU5229400A (en) 2000-12-28
EP1183368B1 (de) 2012-04-18
ATE448244T1 (de) 2009-11-15
WO2000075336A2 (fr) 2000-12-14
EP1181314B8 (de) 2010-02-17
US20080248044A1 (en) 2008-10-09
EP2267132B1 (de) 2014-07-16
FR2794370B1 (fr) 2003-10-17
DE60043299D1 (de) 2009-12-24
EP1181314B1 (de) 2009-11-11
WO2000075336A3 (fr) 2001-07-26
EP1181314A1 (de) 2002-02-27
WO2000075181A1 (fr) 2000-12-14
US6783763B1 (en) 2004-08-31
US20050033025A1 (en) 2005-02-10
EP1183368A2 (de) 2002-03-06
ES2509901T3 (es) 2014-10-20
EP2267132A2 (de) 2010-12-29
US7288258B2 (en) 2007-10-30
ES2386803T3 (es) 2012-08-31
EP2267132A3 (de) 2011-04-20
FR2794370A1 (fr) 2000-12-08
CA2375602A1 (fr) 2000-12-14
AU5411000A (en) 2000-12-28
CA2375627A1 (en) 2000-12-14

Similar Documents

Publication Publication Date Title
ATE448244T1 (de) Proteinfragmente die polyepitope des nef proteins von hiv umfassen, deren herstellung und verwendungen insbesondere zur impfung
ATE236261T1 (de) Dna-expressionssysteme basierend auf alphaviren
ATE423204T1 (de) Herstellung und reinigung von hepatitis c virus- ähnlichen partikeln
JPS60115528A (ja) ヒトインタ―ロイキン―２蛋白質を含有する抗腫瘍用または免疫機能低下疾患治療用組成物
JP4047176B2 (ja) 培地添加剤および動物細胞培養用培地
JP7728755B2 (ja) 細胞を再プログラム化して形質細胞様樹状細胞またはｉ型インターフェロン産生細胞に変換する組成物、その方法および用途
ES2561483T3 (es) Antígenos mutantes de GAS57 y anticuerpos de GAS57
RU2401307C1 (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pFK2, ОБЕСПЕЧИВАЮЩАЯ СИНТЕЗ РЕКОМБИНАНТНОГО ПЕПТИДА, ЯВЛЯЮЩЕГОСЯ АНАЛОГОМ ФРАГМЕНТА КАППА-КАЗЕИНА ЧЕЛОВЕКА, СПОСОБ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО ПЕПТИДА И РЕКОМБИНАНТНЫЙ ПЕПТИД, АНАЛОГ ФРАГМЕНТА КАППА-КАЗЕИНА ЧЕЛОВЕКА, ОБЛАДАЮЩИЙ АПОПТОТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К РАКОВЫМ КЛЕТКАМ
ATE88500T1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
ATE169958T1 (de) Herstellung der p1 proteine und impfstoffe gegen gonorrhöe
ATE351904T1 (de) Einem peptid aus antigen muc-1 entsprechende dns zur auslösung einer immunreaktion gegen tumorzellen
ATE464320T1 (de) Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
JPH05501500A (ja) ＴＧＦ―βの生合成構築物
Holtet et al. Receptor‐binding domain of human α2‐macroglobulin Expression, folding and biochemical characterization of a high‐affinity recombinant derivative
CN101041816B (zh) 人工抗原递呈细胞及其制备方法
DE3686786D1 (de) Menschliche proteine des chinolinesterase-typs und ihre herstellung.
CN110078793A (zh) 一种具有抗衰老和修复作用的多肽及其用途
BR9713540A (pt) Procedimento para a expressão do gene do vìrus da dengue
NO874704D0 (no) Minaktivin fremstilt ved rekombinant dna-teknikk.
EP0676413A3 (de) Interferon alpha/beta bindendes Protein, seine Herstellung und Anwendung.
RU2614124C1 (ru) Оптимизированный ген, кодирующий рекомбинантный белок ипфiii
CN101016540B (zh) C-端含有组氨酸标记的hoxb4重组蛋白质的制造方法及用途
Riding et al. A strategy for purification and peptide sequence analysis of bovine ephemeral fever virus structural proteins
Ivey-Hoyle et al. E2F-2, a novel mammalian transcription factor
Dinic et al. C/EBPα and C/EBPβ are persistently associated with the rat liver nuclear matrix throughout development and the acute phase response